Carboplatin (NSC 241240)

Name: Carboplatin (NSC 241240)
Brand: Selleck Chemicals
SKU: S1215
Rating: 5 (69 reviews)

For research use only.

Catalog No.S1215 Synonyms: JM-8, CBDCA

69 publications

Carboplatin (NSC 241240) Chemical Structure

CAS No. 41575-94-4

Carboplatin (NSC 241240, JM-8, CBDCA) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Selleck's Carboplatin (NSC 241240) has been cited by 69 publications

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Cancer Cell, 2013, 24(5):617-30

PubMed: 24229709 ( click the link to review the publication )

Cell Rep, 2021, 34(10):108814

PubMed: 33691114 ( click the link to review the publication )

Cancer Lett, 2021, 504:137-145

PubMed: 33571541 ( click the link to review the publication )

J Pathol, 2021, 10.1002/path.5652

PubMed: 33620092 ( click the link to review the publication )

Cancers (Basel), 2021, 13(6)1442

PubMed: 33810010 ( click the link to review the publication )

Cancers (Basel), 2021, 13(5)956

PubMed: 33668819 ( click the link to review the publication )

Eur J Pharmacol, 2021, 895:173887

PubMed: 33482182 ( click the link to review the publication )

Sci Adv, 2021, 7(6)eabc8346

PubMed: 33536206 ( click the link to review the publication )

Nat Commun, 2020, 24;11(1):1975

PubMed: 32332851 ( click the link to review the publication )

Nat Commun, 2020, 22;11(1):2573

PubMed: 32444794 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(4):e11177

PubMed: 32115889 ( click the link to review the publication )

Cancer Res, 2020, 80(4):890-900

PubMed: 31857293 ( click the link to review the publication )

Cancer Lett, 2020, 472:59-69

PubMed: 31866467 ( click the link to review the publication )

Sci Signal, 2020, 13(619)

PubMed: 32071169 ( click the link to review the publication )

Cell Death Dis, 2020, 11(11):975

PubMed: 33184273 ( click the link to review the publication )

Br J Cancer, 2020, 3

PubMed: 32242101 ( click the link to review the publication )

J Clin Med, 2020, 28;9(4) pii: E924

PubMed: 32231055 ( click the link to review the publication )

Cells, 2020, 9(6):E1474

PubMed: 32560232 ( click the link to review the publication )

Mol Cancer Ther, 2020, 25;molcanther.1021.2019

PubMed: 32451331 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(8):2649-2676

PubMed: 32905466 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

J Biomed Sci, 2020, 27(1):42

PubMed: 32169072 ( click the link to review the publication )

J Gynecol Oncol, 2020, 31(3):e28

PubMed: 31912682 ( click the link to review the publication )
Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Mol Cell Oncol, 2020, 7(6):1805094

PubMed: 33235906 ( click the link to review the publication )

Cancer Lett, 2020, S0304-3835(20)30647-9

PubMed: 33278498 ( click the link to review the publication )

Neuropathol Appl Neurobiol, 2020, 10.1111/nan.12641

PubMed: 32603552 ( click the link to review the publication )

Front Microbiol, 2020, 10:2936

PubMed: 32038511 ( click the link to review the publication )

Oncotarget, 2020, 11(40):3660-3674

PubMed: 33088426 ( click the link to review the publication )

Oncotarget, 2020, 17;11(11):969-981

PubMed: 32215185 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(19):5925-5936

PubMed: 31300448 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):199

PubMed: 31362778 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):714

PubMed: 31558709 ( click the link to review the publication )

Sci Rep, 2019, 9(1):11153

PubMed: 31371750 ( click the link to review the publication )

Mol Hum Reprod, 2019, 25(10):601-613

PubMed: 31393565 ( click the link to review the publication )

Biol Res, 2019, 52(1):13

PubMed: 30894224 ( click the link to review the publication )

Oncotarget, 2019, 10(65):6981-6996

PubMed: 31857852 ( click the link to review the publication )

Oncotarget, 2019, 10(49):5011-5019

PubMed: 31489111 ( click the link to review the publication )

Oncotarget, 2019, 10(62):6691-6712

PubMed: 31803363 ( click the link to review the publication )

Mol Ther, 2018,

PubMed: 29724685 ( click the link to review the publication )

Cancer Lett, 2018, 436:75-86

PubMed: 30120964 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Neoplasia, 2018, 20(8):826-837

PubMed: 30015158 ( click the link to review the publication )

SLAS Discov, 2018, 23(7):687-696

PubMed: 29865911 ( click the link to review the publication )

Oncol Lett, 2018, 16(6):7131-7138

PubMed: 30546448 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28456-28473

PubMed: 29983873 ( click the link to review the publication )
Clin Cancer Res, 2017, 23(6):1397-1406

PubMed: 27663600 ( click the link to review the publication )

Cell Rep, 2017, 19(1):101-113

PubMed: 28380350 ( click the link to review the publication )

Breast Cancer Res, 2017, 19(1):93

PubMed: 28810913 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28060758 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51733-51747

PubMed: 28881682 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2017, 8:317-329

PubMed: 28918032 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28086243 ( click the link to review the publication )

Sci Rep, 2017, 7:42319

PubMed: 28176879 ( click the link to review the publication )

Nat Commun, 2016, 7:12351

PubMed: 27484502 ( click the link to review the publication )

Nat Commun, 2016, 7:12088

PubMed: 27357444 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(17):E2373-82

PubMed: 27071093 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-16-0004

PubMed: 27256375 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71696-71702

PubMed: 27765934 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

J Transl Med, 2015, 13:239

PubMed: 26198537 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 26047477 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27923-37

PubMed: 26314846 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(14):3849-61

PubMed: 24850841 ( click the link to review the publication )

University of South Florida, 2014, /

PubMed: / ( click the link to review the publication )

PLoS One, 2013, 8(9):e72637

PubMed: 24039787 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description

Features

This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).^[6]

Targets

DNA synthesis ^[1]
(A2780, SKOV-3, IGROV-1, HX62 cells)

In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. ^[1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Tca8113/ut	Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVKyMVI26oDLzszN	MlHnO\|IhcA>?		NWm0PWxscW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|N{GwOUc,OjZzM{exNFU9N2F-
Tca8113/CBP	NVTz[\|ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\BZlIuOjYkgJpOwG0>	NXTmPG55PzJiaB?=		M17SPYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|N{GwOUc,OjZzM{exNFU9N2F-
Tca8113/PYM	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1GxVlIuOjYkgJpOwG0>	NV;4SGJyPzJiaB?=		NGrnUI9qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	NI\lWm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO\|ExPSd-Mk[xN\|cyODV:L3G+
SKOV3	MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDlOYN[PjBibXevcYw>	NI\1Z3UyNTViZB?=		Mmr2bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHlidHnt[UBl\XCnbnTlcpRtgQ>?	NXvybI8xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|cxPDNpPkK2NVM4ODR\|PD;hQi=>
SKOV3	NEW1V5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3voVFAuPCEQvHevcYw>	M4nlfVI1NzR6L{eyJIg>		MoXUbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>?	NX3KR5VbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlUzPzNpPkK2NVI2Ojd\|PD;hQi=>
SKOV3	MYfBdI9xfG:\|aYOgRZN{[Xl?	NX20TZNNOiEQvHevcYw>	NXPNZ5NCPDhiaB?=		M3LWRolv\HWlZYOgZZBweHSxc3nz	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{NUK3N{c,OjZzMkWyO\|M9N2F-
OSA	MXrDcI9vd2enbnnjJGF{e2G7	MmPnNk42NzVizszN			NF71PXVz\XO3bITzJIlvKGyxd3XyJINwdG:weTDmc5Ju[XSrb36gZZMh[2:vcHHy[YQhfG9iZXn0bIVzKEKPSUGgd4lTVkFidILlZZRu\W62	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzME[yNEc,OjZzMUC2NlA9N2F-
A549	NX;HeGZlTnWldHnvckBCe3OjeR?=	Ml3GNE8zPS93MDFOwG0>	MofyNlQhcA>?		Mkjk[I94dnKnZ4XsZZRmeyCvaWKtNlA2KGW6cILld5Nqd28EoB?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
H1975	MlP1SpVkfGmxbjDBd5NigQ>?	MmTGNE8zPS93MDFOwG0>	MkS3NlQhcA>?		NWDrU\|Z4\G:5boLl[5Vt[XSnczDtbXIuOjB3IHX4dJJme3Orb39CpC=>	NXntR3NvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NVc{OTdpPkK1PVE4OzF5PD;hQi=>
A549	NUiyUHgzTnWldHnvckBCe3OjeR?=	Ml;1NE8zPS93MDFOwG0>	M4\kdVI1KGh?		NEn0cZJ2eHKnZ4XsZZRmeyCvaWKtNlE5KGW6cILld5Nqd25?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
H1975	M3vJO2Z2[3Srb36gRZN{[Xl?	NWnXb2FpOC9{NT:1NEDPxE1?	NGTHZm0zPCCq		NWTOSmZTfXC{ZXf1cIF1\XNibXnSMVIyQCCneIDy[ZN{cW:w	MlH1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUezNVcoRjJ3OUG3N\|E4RC:jPh?=
A549	Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nmOFI2KM7:TR?=	NEPVZ2kzPCCq		MmrrbY5pcWKrdIOgZ4VtdCCpcn;3eIg>	NYfYN2hIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NVc{OTdpPkK1PVE4OzF5PD;hQi=>
H1975	MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXUUVZXOjVizszN	MnfNNlQhcA>?		NV7mdmx5cW6qaXLpeJMh[2WubDDndo94fGh?	MnHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUezNVcoRjJ3OUG3N\|E4RC:jPh?=
MDA-MB-231	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHpT2MxNTJ{MDFOwIcwdWx?	Ml\2O\|IhcA>?		MlfzTWM2OMLiPTC4OkDPxE1?	M2CwR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO3OlkyLz5{NUizO\|Y6OTxxYU6=
T47D	NF\1U5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTISGZ6OC1{MkCg{txoN22u	MmPBO\|IhcA>?		NGfXU4JKSzVywrC9JFQ5NjlizszN	NEjqSms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizO\|Y6OSd-MkW4N\|c3QTF:L3G+
LCTCC	Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEWyPHlKSzVyPUOuPQKBkcL3TR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd5M{G2O{c,OjV5N{OxOlc9N2F-
MCTCC	NXHBXYZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH:4VWJKSzVyPUKuPQKBkcL3TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd5M{G2O{c,OjV5N{OxOlc9N2F-
MegTCC	NVf0UWRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTtTWM2OD12LkJihKnDvU1?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd5M{G2O{c,OjV5N{OxOlc9N2F-
MonoTCC	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3GzTmlEPTB;NT625qCKyrWP	NEi0OoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3N\|E3Pyd-MkW3O\|MyPjd:L3G+
MCF7	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;BV3RlOjBizszN	M4LjPVczKGh?		NV2y[nljcW6mdXPld{Bk\WyuIHTlZZRpKG:oIFjQNe6zNWSncHzleIVlKE2FRkegZ4VtdHN?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4OUCyOUc,OjV5NkmwNlU9N2F-
A-549	NIj5UYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HTRVAvPSEQvF2=	Mm\uNlQhcA>?	M4TzVGROW00EoB?=	MWnpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7	NGL6OZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1OVY6OCd-MkW3OVU3QTB:L3G+
A-549	NX\NRmNISXCxcITvd4l{KEG\|c3H5	MU[wMlUh\|ryP	Mn3COFghcA>?	MYjEUXNQyqB?	NI\nUIF{cG:5czDlZZJtgSCjcH;weI9{cXNiZnXheJVz\XNiaX7jcJVlcW6pIHLs[YJjcW6pIHHu[EBkcHKxbXH0bY4h[2:wZHXud4F1cW:w	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3NU[5NEc,OjV5NUW2PVA9N2F-
A-549	NEXmW5VHfWO2aX;uJGF{e2G7	MV:wMlUh\|ryP	NUPaSZd6PDhiaB?=	M33kWGROW00EoB?=	M3XvRZNpd3e\|IHHi[ZJz[W62IH3pZ5JwfHWkdXzlJIRqe3K3cITpc44>	NEDZeXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1OVY6OCd-MkW3OVU3QTB:L3G+
A-549	NV:yVYFtTnWldHnvckBCe3OjeR?=	MnLDNE42KM7:TR?=	M2Hpc\|Q5KGh?	NVvVWIxpTE2VT9Mg	MlXtbY5pcWKrdIOgc4Yh[2WubDDtbYdz[XSrb39CpC=>	M4fmTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{W1OlkxLz5{NUe1OVY6ODxxYU6=
RMG-1	NUewemM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPUcWljUUN3ME2yPE45KMLzIEOuOkBu\y:O	NYHyXIdMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlY6OTNpPkK1O\|I3QTF\|PD;hQi=>
FN-RMG-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTRyLkWgxtEhPC5{IH3nM2wLKM7:TR?=	Mm\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mk[5NVMoRjJ3N{K2PVE{RC:jPh?=
RMG-1-hFUT	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHtTGQxUUN3ME21PE4yKMLzIEKuOEBu\y:O	NULRUoVCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlY6OTNpPkK1O\|I3QTF\|PD;hQi=>
FN-RMG-1-hFUT	Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTFzOD64JOKyKDF\|LkigcYcwVA>?	NXT2b3ZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlY6OTNpPkK1O\|I3QTF\|PD;hQi=>
CHP-134	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWSxJO69VQ>?		MXrEUXNQyqB?	MULpcohq[mm2czDzbYdvcW[rY3HueEBk\WyuIHfyc5d1cCClb33ibY5m\CC5aYToJGdUUzJ6M{CzO\|E>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OES2N{c,OjV4NUi0OlM9N2F-
IMR-32	NIjL[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDMZVFVOSEQvF2=		Mo\FSG1UV8Li	Mn;obY5pcWKrdIOgd4lodmmoaXPhcpQh[2WubDDndo94fGhiY3;tZolv\WRid3n0bEBIW0t{OEOwN\|cy	MomxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUi0OlMoRjJ3NkW4OFY{RC:jPh?=
CHP-134	MlXuSpVkfGmxbjDBd5NigQ>?	NXr0OWdpOTBizszNxsA>		MV;EUXNQyqB?	NIX5RVVqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>?	M{DNN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW4OFY{Lz5{NU[1PFQ3OzxxYU6=
IMR-32	MX;GeYN1cW:wIFHzd4F6	NFjKOVgyOCEQvF5CpC=>		MkPPSG1UV8Li	MnLrbY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJGdUUzJ6M{CzO\|E>	MkmwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUi0OlMoRjJ3NkW4OFY{RC:jPh?=
A549	M2T4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TyOVAvOi12MECwJO69VQ>?	Mm\GO\|IhcA>?		Mn3ITWM2OD1zMk[gxtEhPS5yIN88US=>	Mn[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkWyOFMoRjJ3NkK1NlQ{RC:jPh?=
A549/CDDP	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXe2Sm9JOC5{LUSwNFAh\|ryP	MXy3NkBp		NWT1[JA2UUN3ME2yOFDDqMLzwrC0OU44KM7:TR?=	NULTeYR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlUzPDNpPkK1OlI2OjR\|PD;hQi=>
H460	MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2jrXFI1KGh?	NGT0bmpFVVOR	NYjKZmllUUN3ME23Mlkh\|ryP	NWHaWlNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVk6QTVpPkK1OVk6QTl3PD;hQi=>
H460	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHIUJc4NjlizszN	MoS1NlQhcA>?	NFmzNolFVVOR	MlXsd4hwf3NiYTDyZYRqd3OnboPpeIl7cW6pIHXm[oVkfCC2bzDYMZJigXN?	NU\u[YlXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVk6QTVpPkK1OVk6QTl3PD;hQi=>
NRK-52E	Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmLqO\|LDqGkEoB?=		MoHxTWM2OD1zMECgxtEhOTJwOTFOwG0>	NVTXUpo3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlU3ODNpPkK1OVY2PjB\|PD;hQi=>
RGE	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV7SdY1PPzMEoHlCpC=>		M3jreWlEPTB;MkKgxtEhPy52IN88US=>	NXnpbWtuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlU3ODNpPkK1OVY2PjB\|PD;hQi=>
NRK-52E	MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4PKVVczyqCqwrC=		M17sUmlEQDB;MUe5JOKyKDlwNTFOwG0>	MlTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NkW2NFMoRjJ3NU[1OlA{RC:jPh?=
RGE	NW\pfYJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MofWO\|LDqGkEoB?=		M1XUfGlEQDB;NkOgxtEhPy52IN88US=>	MmO2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NkW2NFMoRjJ3NU[1OlA{RC:jPh?=
SK-OV-3	NWe5bINuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3ezPVczKGh?		NYG1VXJPUUN3ME2xNFQvQCEQvF2=	MlnJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkCxN\|IoRjJ3NUKwNVMzRC:jPh?=
ES-2	NXTsdZdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHTQWVI4OiCq		MlvYTWM2OD1zND62JO69VQ>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN\|I9N2F-
OVCAR-8	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2XtWlczKGh?		MkjSTWM2OD17Nj6wJO69VQ>?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN\|I9N2F-
3AO	Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUDqeYVIPzJiaB?=		NVLVZXl3UUN3ME22N{41KM7:TR?=	NHn1RlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyNFE{Oid-MkW1NlAyOzJ:L3G+
A2780	NGXTWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4jNcVczKGh?		M3jIWWlEPTB;MUS1Mlch\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN\|I9N2F-
SW626	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1i4bVczKGh?		NHy5UXhKSzVyPUm3MlAh\|ryP	M{G0fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUKwNVMzLz5{NUWyNFE{OjxxYU6=
OVCAR-3	M3T5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{\kS\|czKGh?		NEjpeJZKSzVyPUOyMlYh\|ryP	MnTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkCxN\|IoRjJ3NUKwNVMzRC:jPh?=
A549	M3u3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{H6[WlEPTB;MUWxMlU3KMLzIEWzMlA3KM7:TR?=	NF;3SoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|Q3OSd-MkWyO\|c1PjF:L3G+
4T1	NFnVdWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzVPIlGUUN3ME24OE43OiEEsTCzNE4xPSEQvF2KJO69VQ>?	NITYWGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|Q3OSd-MkWyO\|c1PjF:L3G+
BALB/3T3	MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\iTWM2OD1zND6zNEDDuSB4Lk[4JO69VQ>?	MlXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
B16	MoDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXWTWM2OD14ND6zNEDDuSB4LkixJO69VQ>?	MoWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
DU 145	NX3TR4ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3u0bWlEPTB;M{WuNFQhyrFiMUeuOVQh\|ryP	NWDQXVMyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PjFpPkK1Nlc4PDZzPD;hQi=>
FaDu	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fUdmlEPTB;NEWuN\|khyrFiMUGuOVAh\|ryP	M2TxU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O\|Q3OTxxYU6=
HCV-29T	NWT3eXhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4CzdmlEPTB;NEiuOVchyrFiMkKuOFkh\|ryP	MoDJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
HL-60	Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTFzLkGwJOKyKDRwNEeg{txO	M1nWfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O\|Q3OTxxYU6=
HT-29	NVe2b4pYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDPT3JKSzVyPUi5MlE3KMLzIEG4Mlg3KM7:TR?=	NIK2enc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|Q3OSd-MkWyO\|c1PjF:L3G+
H146	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3f6R2lEPTB;NEmuOuKyOTNwMTFOwG0>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H187	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHO4NmVKSzVyPUGyMlfDuTJwNzFOwG0>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H128	NVjmWWZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrrTWM2OD1zME[uOOKyQS54IN88US=>	NHnqS2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyOFI5Oid-MkWxNlQzQDJ:L3G+
H69	NWP5WXJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjTOmFKSzVyPUe2MlnDuTJ5Lkig{txO	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H209	NH7seJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXL6[4czUUN3ME2yOVgvOcLzOUmuPEDPxE1?	NVvrOYMyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
DMS153	MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrITWM2OD13Nz64xtE6NjJizszN	NUTQ[lNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
H526	M1PQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{e0emlEPTB;Nz6yxtEyNjdizszN	MnLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
DMS114	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjSTWM2OD16NT64xtEyOi56IN88US=>	NWrqUndQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
DMS53	M{DIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4j6U2lEPTB;MUS2MlLDuTN4LkSg{txO	Mn;aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
HeLa	MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fDWFUuQDBizszN			M2i1NolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk>	MmTNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEmzOlAoRjJ3MUC5N\|YxRC:jPh?=
MCF-7	NIqz[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDkOFI2NThyIN88US=>			M1KzRolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk>	NFuzc3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwPVM3OCd-MkWxNFk{PjB:L3G+
MDA-MB-231	NUXaTJZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF[0VGg2NThyIN88US=>			NYLmfG5zcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyOUO2NEc,OjVzMEmzOlA9N2F-
CaOV3	NFnCW\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVK3NkBp		M3fVR2lEPTB;OE[uNUDPxE1?	MorzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNki4OFkoRjJ3ME[4PFQ6RC:jPh?=
OVCAR-3	M{X2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2rTZ\|czKGh?		NFO3V45KSzVyPUG3PU42KM7:TR?=	M3[xSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[4PFQ6Lz5{NUC2PFg1QTxxYU6=
OVCAR-5	M3zTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYq3NkBp		M2mxUWlEPTB;N{WuO{DPxE1?	NFPrNpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2PFg1QSd-MkWwOlg5PDl:L3G+
SKOV-3	NYfi[lN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUe3NkBp		MmjvTWM2OD13MESg{txO	NFO1bms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2PFg1QSd-MkWwOlg5PDl:L3G+
OVCAR-4	NUfNSHp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVzTXlJEPzJiaB?=		MnzzTWM2OD1{OUCuOkDPxE1?	NFTaU209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2PFg1QSd-MkWwOlg5PDl:L3G+
OVCAR-8	NFLJR4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmDwO\|IhcA>?		NV7XNmh3UUN3ME22PVAvOiEQvF2=	NF\1Zos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2PFg1QSd-MkWwOlg5PDl:L3G+
MA148	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnGyNlQhcA>?		MnfZTWM2OD16Mz625qCKyrIkgJmxMlQh\|rypL33s	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|MUC5NUc,OjR6M{GwPVE9N2F-
A549	M3rPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIHoSXEzPCCq		NGHiVXlKSzVyPUe3Ok4x6oDLwsJihKkyNjlizsznM41t	M4LjdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
MDA-MB-231	NGfLcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIm1bWQzPCCq		NIrWcIpKSzVyPUe0PE4x6oDLwsJihKkyNjFizsznM41t	NWn5OWtwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|ExQTFpPkK0PFMyODlzPD;hQi=>
NCI-ADR/RES	NXrTRnRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWXmV5ZCOjRiaB?=		MW\JR\|UxRTF5NUOuNQKBkcLz4pEJOE41KM7:Zz;tcC=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|MUC5NUc,OjR6M{GwPVE9N2F-
MA148	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlnEOFghcA>?		Ml[2TWM2OD1{OD6x5qCKyrIkgJmxMlAh\|rypL33s	MmPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
A549	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NY\nUHBHPDhiaB?=		MkGxTWM2OD1zMUiuNQKBkcLz4pEJNU4zKM7:Zz;tcC=>	NWnyN4RZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|ExQTFpPkK0PFMyODlzPD;hQi=>
MDA-MB-231	MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2\DelQ5KGh?		NEnaSWlKSzVyPUG4N{4x6oDLwsJihKkyNjJiIN88[{9udA>?	NXHxUXFrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|ExQTFpPkK0PFMyODlzPD;hQi=>
NCI-ADR/RES	M2rheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnrPOFghcA>?		NIjjU2FKSzVyPUG5N{4x6oDLwsJihKkyNjlizsznM41t	NXv1[FRnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|ExQTFpPkK0PFMyODlzPD;hQi=>
MA148	M2n1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFLUTnI4OiCq		NF;iemVKSzVyPUGzMlfjiIoEsfMAjVEvOiEQvHevcYw>	NGqzUHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N\|ExQTF:L3G+
A549	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXfp[2t3PzJiaB?=		NWT2SlZoUUN3ME22OE4{6oDLwsJihKkyNjFizsznM41t	NYnSb4U5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|ExQTFpPkK0PFMyODlzPD;hQi=>
MDA-MB-231	M2ewZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{P5SFczKGh?		NIjRWI5KSzVyPUm5MlXjiIoEsfMAjVEvOSEQvHevcYw>	MmHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
NCI-ADR/RES	NYrxemVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYG3NkBp		NIfE[\|RKSzVyPUO3MlTjiIoEsfMAjVEvPyEQvHevcYw>	NU\PfIt2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|ExQTFpPkK0PFMyODlzPD;hQi=>
A549	NEn1RnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHnRUJg4OiCq	MYrEUXNQ	MofOTWM2OD1zNUKuOFA6KM7:TR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{MUOyN{c,OjR5MkGzNlM9N2F-
NCI-H157	NWSwbVRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml;tO\|IhcA>?	MlzKSG1UVw>?	MmX6TWM2OD16OT65O\|ch\|ryP	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{MUOyN{c,OjR5MkGzNlM9N2F-
PC9	MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIrmR4Q4OiCq		Mlj5S2M2OD15MT62xtE6NjViwsXN	NYrDW2d3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NVg5ODlpPkK0OlE5QDB7PD;hQi=>
A549	Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV3jfWROPzJiaB?=		M2fRSGdEPTB;MUO2xtE{OS54INM1UeKh	M4nNXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkG4PFA6Lz5{NE[xPFgxQTxxYU6=
PC9	M3fWZWFxd3C2b4Ppd{BCe3OjeR?=	M4rmfFExOCEEtV2=	MlO5O\|IhcA>?		NV[0VnNkcW6mdXPld{BieG:ydH;zbZM>	M1fLXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkG4PFA6Lz5{NE[xPFgxQTxxYU6=
A549	MmPlRZBweHSxc3nzJGF{e2G7	NVfGUoUxOTByINM1US=>	M4C1b\|czKGh?		M4ezfolv\HWlZYOgZZBweHSxc3nz	M2rITFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkG4PFA6Lz5{NE[xPFgxQTxxYU6=
A549	M3zocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFvyW4czPCCq		M1y2WGlEOTB;MT60O\|Yhdk1?	NWWzbIxpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVY1OzdpPkK0N\|k3PDN5PD;hQi=>
H1299	NHLQOo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIrG[nAzPCCq		NH73eopKSzFyPUCuOFQ{KG6P	M1PvOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{m2OFM4Lz5{NEO5OlQ{PzxxYU6=
HCC15	NXm1UoJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2PEeVI1KGh?		NX\rcZFoUUNzME2wMlM1PiCwTR?=	NHHlUIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO5OlQ{Pyd-MkSzPVY1Ozd:L3G+
H157	NXf2XIxlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFHqToszPCCq		NUnTO3B4UUNzME2wMlgyKG6P	NXrBdpEyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVY1OzdpPkK0N\|k3PDN5PD;hQi=>
A2780	M2\QR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlP0TWM2OD1zND6w5qCKyrIkgJmxMlQh\|ryP	M4fSTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkC5Olk{Lz5{NEKwPVY6OzxxYU6=
A2780cisR	M2LuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DRV2lEPTB;NEiuPgKBkcLz4pEJN{46KM7:TR?=	M4H0T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkC5Olk{Lz5{NEKwPVY6OzxxYU6=
A2780ZD0473R	M{XWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTZ2LkdihKnDueLCiUOuNkDPxE1?	NGHjN\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKwPVY6Oyd-MkSyNFk3QTN:L3G+
SKOV-3	NITGfHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXFTWM2OD12Mz605qCKyrIkgJmzMlkh\|ryP	NVjkV21qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNFk3QTNpPkK0NlA6Pjl\|PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pChK-2 / Chk-2 ; PubMed: 30049957 Int J Mol Sci Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated Chk-2. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ p-p53(S15) / p-p53(S46) / p-p53(S392) / p53; PubMed: 30049957 Int J Mol Sci Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated p-p53. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ p-p38 / p38 / Cleaved PARP / PARP ; PubMed: 30049957 Int J Mol Sci A2780s and A2780cp cells were treated with increasing concentrations of carboplatin for 48 h. Phosphorylation of p38 and cleavage of Poly(ADP-ribose) polymerase (PARP) were analyzed by Western blotting. Two antibodies were used to examine the cleaved PARP䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋Ð㺣痖�෋𢡄�෋䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemｾ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒ｾ᎒�堞ﻮ᎒፲露𢡄	30049957
Immunofluorescence	γH2AX ; PubMed: 24348048 Onco Targets Ther Carboplatin induced DNA damage in SiHa cells. SiHa cells were exposed to 20, 40, and 80 μmol/L carboplatin for 12 hours, respectively. Immunofluorescence analysis was used to detect nuclear γ-H2AX foci formation with anti-H2AX antibody (red, fluorescein i䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ	24348048
Growth inhibition assay	Cell viability ; PubMed: 24348048 Onco Targets Ther SiHa and CaSki cells were treated with the indicated concentrations of carboplatin for 72 hours, and cell viability was measured by Cell Counting Kit-8 viability assay.	24348048

In vivo

In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. ^[1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. ^[3]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: A2780, SKOV3, IGROV-1 and HX62
Concentrations: 0-200 μM
Incubation Time: 72 hours
Method:
3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.

(Only for Reference)

Animal Research:

^[1]

- Collapse

Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
Dosages: ≤60 mg/kg (When Carboplatin is dissolved in sodium chloride solution, it will induce physio-chemical and pharmacokinetic changes.)
Administration: Administered via i.p.
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	Water	14 mg/mL warmed (37.71 mM)
	DMSO	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Carboplatin (NSC 241240) SDF

Molecular Weight	371.25
Formula	C₆H₁₂N₂O₄Pt
CAS No.	41575-94-4
Storage	2 years 4°C(in the dark) powder
Synonyms	JM-8, CBDCA
Smiles	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04606914	Not yet recruiting	Drug: mirvetuximab soravtansine (MIRV; IMGN853)	Ovarian Cancer\|Fallopian Tube\|Primary Peritoneal Cancer	University of Alabama at Birmingham	March 31 2021	Phase 2
NCT04865250	Recruiting	Drug: Atezolizumab	NSCLC Stage II\|NSCLC Stage IIIA\|NSCLC Stage IIIB	University Hospital Heidelberg\|Roche Pharma AG	January 7 2021	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Can you advise what solvent to use and the concentration for S1215 for in vitro use?
Answer:
DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

Choose Your Country or Region

By Signaling Pathways

By product type

Carboplatin (NSC 241240)